Search company, investor...

Verismo Therapeutics's alternatives and competitors

See how Verismo Therapeutics compares to similar products. Verismo Therapeutics's top competitors include TCR2 Therapeutics, and Lyell.

TT

TCR2 Therapeutics (NASDAQ: TCRR) is a discovery-stage pharmaceutical company that focuses on engineering T cells for cancer therapy. The company's expertise in T cell e…

Verismo Therapeutics vs. TCR2 Therapeutics

View Verismo Therapeutics's entire Analyst Briefing

Verismo Therapeutics's Analyst Briefing includes information on:

  • Pricing
  • Customer references
  • Products
CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
  • LY

    Lyell (NASDAQ: LYEL) operates as a cellular therapy company. The company offers T lymphocyte cell (T-cell) reprogramming technologies designed to address major barriers…

    Verismo Therapeutics vs. Lyell

    View Verismo Therapeutics's entire Analyst Briefing

    Verismo Therapeutics's Analyst Briefing includes information on:

    • Pricing
    • Customer references
    • Products
CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Top 2 Verismo Therapeutics competitors

Compare Verismo Therapeutics to Competitors

T
TCR2 Therapeutics

TCR2 Therapeutics (NASDAQ: TCRR) is a discovery-stage pharmaceutical company that focuses on engineering T cells for cancer therapy. The company's expertise in T cell engagement and an understanding of T cell receptor biology helps to kill cancer cells by harnessing the entire TCR signaling complex. The company was founded in 2015 and is based in Cambridge, Massachusetts. In June 2023, TCR2 Therapeutics was acquired by Adaptimmune at a valuation of $110M.

L
Lyell

Lyell (NASDAQ: LYEL) operates as a cellular therapy company. The company offers T lymphocyte cell (T-cell) reprogramming technologies designed to address major barriers to successful adoptive cell therapy (ACT) for solid tumors. It was founded in 2018 and is based in South San Francisco, California.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.